MA53020A - Protéine de fusion du fviii améliorée et utilisation associée - Google Patents

Protéine de fusion du fviii améliorée et utilisation associée

Info

Publication number
MA53020A
MA53020A MA053020A MA53020A MA53020A MA 53020 A MA53020 A MA 53020A MA 053020 A MA053020 A MA 053020A MA 53020 A MA53020 A MA 53020A MA 53020 A MA53020 A MA 53020A
Authority
MA
Morocco
Prior art keywords
fusion protein
associated use
fviii fusion
enhanced fviii
enhanced
Prior art date
Application number
MA053020A
Other languages
English (en)
Inventor
Xian Chen
Jie Gao
Haitao Hu
Lingli Huang
Xiang Li
Bin Liu
Zijia Ren
Hongsheng Su
Qilei Wang
Shuang Wang
Shuya Wang
Wenwen Wang
Xiaoshan Wang
Yali Wang
Chunfeng Xiao
Lili Zhang
Luyan Zhu
Original Assignee
Zhengzhou Gensciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhengzhou Gensciences Inc filed Critical Zhengzhou Gensciences Inc
Publication of MA53020A publication Critical patent/MA53020A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA053020A 2018-05-18 2019-05-16 Protéine de fusion du fviii améliorée et utilisation associée MA53020A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810481941 2018-05-18

Publications (1)

Publication Number Publication Date
MA53020A true MA53020A (fr) 2021-05-05

Family

ID=68539524

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053020A MA53020A (fr) 2018-05-18 2019-05-16 Protéine de fusion du fviii améliorée et utilisation associée

Country Status (9)

Country Link
US (1) US20210361775A1 (fr)
EP (1) EP3816181A4 (fr)
JP (2) JP2021530437A (fr)
KR (1) KR102575788B1 (fr)
CN (2) CN117467019A (fr)
BR (1) BR112020023168A2 (fr)
MA (1) MA53020A (fr)
MX (1) MX2020012103A (fr)
WO (1) WO2019219049A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023227015A1 (fr) * 2022-05-25 2023-11-30 江苏晟斯生物制药有限公司 Conjugué de protéine de fusion fviii ayant une demi-vie étendue et son utilisation
CN116284411B (zh) * 2023-02-03 2024-02-13 北京基科晟斯医药科技有限公司 抗培重组人凝血因子VIII-Fc融合蛋白的抗体及其应用
CN116036244B (zh) * 2023-02-24 2023-09-19 北京基科晟斯医药科技有限公司 培重组人凝血因子VIII-Fc融合蛋白用于治疗含抑制物的血友病A的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818679A (en) 1985-02-19 1989-04-04 The Trustees Of Columbia University In The City Of New York Method for recovering mutant cells
AU8576298A (en) * 1997-07-18 1999-02-10 Chiron Corporation Lentiviral vectors
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
WO2011101242A1 (fr) * 2010-02-16 2011-08-25 Novo Nordisk A/S Molécules de facteur viii avec liaison réduite au vwf
US9493543B2 (en) * 2010-02-16 2016-11-15 Novo Nordisk A/S Factor VIII fusion protein
AU2012318292B2 (en) * 2011-10-18 2015-08-20 Csl Limited Method for improving the stability of purified Factor VIII after reconstitution
CN103172745A (zh) * 2011-12-21 2013-06-26 北京韩美药品有限公司 包含免疫球蛋白Fc片段的长效人内皮抑素
KR102212098B1 (ko) * 2012-01-12 2021-02-03 바이오버라티브 테라퓨틱스 인크. 키메라 인자 viii 폴리펩티드들과 이의 용도
EP2870250B2 (fr) * 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Lignée cellulaire exprimant des polypeptides de facteur viii à une seule chaîne et ses utilisations
EP2882457A1 (fr) * 2012-08-13 2015-06-17 Novo Nordisk A/S Formulations liquides de facteur viii
ES2657291T3 (es) * 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
KR20180094114A (ko) * 2016-01-07 2018-08-22 체에스엘 베링 리컴비넌트 퍼실리티 아게 돌연변이된 절단된 폰 빌레브란트 인자
CN109790529A (zh) * 2016-06-24 2019-05-21 财团法人牧岩生命科学研究所 包含FVIII和vWF因子的嵌合蛋白及其用途
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途

Also Published As

Publication number Publication date
KR20210005248A (ko) 2021-01-13
CN117467019A (zh) 2024-01-30
CN113039200B (zh) 2023-07-25
KR102575788B1 (ko) 2023-09-08
US20210361775A1 (en) 2021-11-25
JP2023093634A (ja) 2023-07-04
EP3816181A1 (fr) 2021-05-05
JP2021530437A (ja) 2021-11-11
BR112020023168A2 (pt) 2021-02-09
EP3816181A4 (fr) 2022-04-20
CN113039200A (zh) 2021-06-25
MX2020012103A (es) 2021-01-29
WO2019219049A1 (fr) 2019-11-21
JP7492780B2 (ja) 2024-05-30

Similar Documents

Publication Publication Date Title
MA44776A (fr) Anticorps anti-vista humain et leur utilisation
MA51291A (fr) Protéines de fusion il-2 fc modifiées
IL281954A (en) Heterodimeric chimeric proteins
IL279510A (en) Progranulin-FC polypeptide fusion proteins and their uses
KR102162129B9 (ko) 항-갈렉틴-9 항체 및 이의 용도
MA44993A (fr) Polypeptides de fusion cd40l-fc et procédés d'utilisation associés
DK3365368T3 (da) Tgfbeta1-bindende immunoglobuliner og anvendelse deraf
DK3280727T3 (da) Enkeltarmede type i- og type ii-receptorfusionsproteiner og anvendelser deraf
DK3368554T3 (da) Langtidsvirkende fgf21-fusionsproteiner og farmaceutisk sammensætning omfattende samme
IL279505A (en) Chimeric transmembrane protein and its uses
MA52284A (fr) Anticorps anti-hla-g et leur utilisation
DK3275895T3 (da) Neuropilin-1-specifikt bindingspeptid, fusionsprotein fusioneret dermed, og anvendelse deraf
MA50908A (fr) Formulations de protéines de fusion vegfr-fc
MA50038A (fr) Anticorps anti-pd-l1 de et son utilisation
MA50440A (fr) Imidazopyridinamides substituées et leur utilisation
MA44777A (fr) Anticorps humanisés anti-basigine et leur utilisation
MA50174A (fr) Formules de protéines de fusion vegfr-fc
IL280103A (en) Fusion protein containing SIRPalpha-4-1BBL and methods of using it
MA53020A (fr) Protéine de fusion du fviii améliorée et utilisation associée
MA44056A (fr) Anticorps anti-rispéridone et leur utilisation
EP3722305A4 (fr) Protéine de fusion hm-3 et son utilisation
DK3737399T3 (da) Atf5-peptidvarianter og anvendelser deraf
SG11202110400QA (en) Fusion protein and use thereof
MA49905A (fr) Polyesteramines et polyesterquats
SG11202101904UA (en) Spd-1 variant - fc fusion proteins